Thrombosis Research
Volume 118, Issue 4 , Pages 487-493 , 2006

Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study

Received 26 May 2005 ,Revised 27 September 2005 ,Accepted 17 October 2005.

References 

  1. Mehta SR, Yusuf S. Short and long-term oral antiplatelet therapy in acute coronary syndromes and PCI. J Am Coll Cardiol. 2003;41:79S–88S
  2. Jilma B. Therapeutic failure and resistance to aspirin. J Am Coll Cardiol. 2003;41:961–965
  3. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg 27: 456–65.
  4. Howard PA. Aspirin resistance. Ann Pharmacother. 2002;36:1620–1624
  5. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 2003;108:115–119
  6. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392–1397
  7. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST elevation myocardial infarction 2002: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 2002;106:1893–1900
  8. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost. 2000;83:316–321
  9. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152–163
  10. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh P, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–235
  11. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel and both after ischemic stroke: a case-crossover study. Stroke. 2003;34:849–854
  12. Jilma B. Synergistic effect of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke. 2003;34:854
  13. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–235
  14. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152–163
  15. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet activity to adenosine diphosphate. Thromb Res. 2002;107:45–49
  16. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1–8
  17. Eikelboom JW, Hankey GJ. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol. 2003;41:966–968
  18. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549–1554
  19. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–3175
  20. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2001;104:81–86
  21. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–1655
  22. Gum PA, Kottke-Merchant K, Welsh P, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965
  23. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004;15:95–99
  24. Chandrasekar B, Tanguay JF. Platelets and restenosis. J Am Coll Cardiol. 2000;35:555–562
  25. Uchida K, Sasahara M, Morigami N, Hazama F, Kinoshita M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis. 1996;124:9–23
  26. Myllarniemi M, Calderon L, Lemstrom K, Buchdunger E, Hayry P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 1997;11:1119–1126
  27. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Int Med. 2002;252:233–238
  28. Gurbel PA, Bliden KP, Bonnie LH, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–2913
  29. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Sobel BE, Schneider D. Platelet reactivity characterized prospectively: a determination of outcome 90 days after percutaneous coronary intervention. Circulation. 2001;104:181–186
  30. Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Brit J Haem. 2004;124:80–85
  31. Kereiakes DJ, Lorenz T, Young JJ, Kukielka G, Mueller MN, Nanniazz-Alaimo L, et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis. 2001;12:123–127

☆ Supported by: Italian National Council of Research.

PII: S0049-3848(05)00422-6

doi: 10.1016/j.thromres.2005.10.011

Thrombosis Research
Volume 118, Issue 4 , Pages 487-493 , 2006

Article Tools

* Image Usage & Resolution